Distinguishing Primary Cutaneous B-Cell Lymphoma from Systemic DLBCL with Skin Involvement
The critical distinction between primary cutaneous B-cell lymphoma and systemic DLBCL involving the skin requires comprehensive staging to exclude extracutaneous disease at diagnosis—if lymph nodes, bone marrow, or other organs are involved, it is systemic DLBCL, not primary cutaneous disease 1, 2.
Staging Workup: The Definitive Differentiator
The most important step is performing a complete staging evaluation to rule out systemic involvement:
- Physical examination: Palpate all lymph node regions systematically
- CT imaging: Chest, abdomen, and pelvis to detect nodal or visceral disease
- Bone marrow biopsy: Essential to exclude marrow involvement
- Laboratory studies: Complete blood count, LDH, comprehensive metabolic panel
If any extracutaneous site is positive at diagnosis, the diagnosis is systemic DLBCL with secondary skin involvement, not primary cutaneous disease 1, 2, 3.
Clinical Presentation Patterns
Primary Cutaneous B-Cell Lymphomas
- Primary cutaneous follicle center lymphoma (PCFCL): Solitary or grouped tumors on head/trunk, indolent behavior 1
- Primary cutaneous DLBCL, leg-type (PCDLBCL-LT): Tumors predominantly on legs in elderly patients, more aggressive 1, 4
- Primary cutaneous marginal zone lymphoma: Papules/plaques on extremities 1
Secondary/Systemic DLBCL
- More commonly presents on trunk and extremities (rather than head/neck) 3
- Often multiple sites of involvement
- Presence of B symptoms (fever, night sweats, weight loss)
- Elevated LDH more common
Histologic and Immunophenotypic Features
Key Distinguishing Features
Primary cutaneous disease typically shows:
- CD10-negative, BCL-6 positive, BCL-2 negative immunoprofile in most PCFCL cases 3
- Absence of t(14;18) translocation by FISH in primary cases 3
- Large cleaved cells in PCFCL (previously misclassified as DLBCL) 1
Systemic DLBCL with skin involvement more often shows:
- CD10+, BCL-6+, BCL-2+ follicular center cell profile 3
- t(14;18) translocation present (found in 0 of 9 primary vs. 3 of 5 secondary cases in one study) 3
- More frequent BCL-2 expression 3
Critical Pathology Requirements
A surgical excision biopsy is mandatory—not fine needle aspiration or small core biopsies 5. The specimen should include:
- Immunohistochemistry panel: CD20, CD79a, BCL-6, CD10, MYC, BCL-2, Ki67, IRF4 5
- FISH for t(14;18) translocation when available 3
- Assessment of architectural pattern and cell morphology 1
Prognostic and Treatment Implications
This distinction is critical for mortality and quality of life:
Primary Cutaneous Disease (PCFCL, PCMZL)
- 5-year survival >95% 2
- Should NOT receive systemic chemotherapy 1, 2
- Local radiation or excision for limited disease 2, 6
- Rituximab monotherapy for widespread skin involvement 2
- Frequent cutaneous relapses but excellent overall survival 1
Primary Cutaneous DLBCL, Leg-Type
- More aggressive with inferior prognosis 2, 4
- Requires systemic chemotherapy (R-CHOP) similar to nodal DLBCL 2
- Frequent relapses and potential extracutaneous dissemination 1
Systemic DLBCL with Skin Involvement
- Requires aggressive systemic chemotherapy 5
- Treated identically to nodal DLBCL
- Worse prognosis than primary cutaneous indolent types 3
Common Pitfalls to Avoid
Do not diagnose primary cutaneous disease without complete staging—this is the most critical error that leads to undertreatment of systemic disease 1, 2
Do not treat PCFCL with large cleaved cells as systemic DLBCL—these patients have indolent disease and systemic chemotherapy is unnecessary and harmful 1
Do not rely on small biopsies or FNA—inadequate tissue prevents proper classification 5
Do not assume leg location alone means PCDLBCL-LT—complete staging is still required to exclude systemic disease 4
Recognize that immunophenotype overlaps exist—some primary cutaneous cases can show follicular center cell markers, making clinical correlation and staging essential 3